RecruitingPhase 3NCT06056297
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Studying Acquired neutropenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- X4 Pharmaceuticals
- Principal Investigator
- Vice President Global Head of Clinical Development and SafetyX4 Pharmaceuticals
- Intervention
- Mavorixafor(drug)
- Enrollment
- 176 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2024 – 2027
Study locations (30)
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- UC Irvine, Irvine, California, United States
- Orso Health, La Jolla, California, United States
- University of California, Los Angeles-UCLA, Los Angeles, California, United States
- Orso Health, Torrance, California, United States
- University of Southern Florida, St. Petersburg, Florida, United States
- Children's Healthcare of Atlanta (CHOA), Atlanta, Georgia, United States
- University of Iowa, Iowa City, Iowa, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Washington University, St Louis, Missouri, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06056297 on ClinicalTrials.govOther trials for Acquired neutropenia
Additional recruiting or active studies for the same condition.